Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
Cancers|November 13, 2021
Salvage Chemotherapy in Patients with Previously Treated Thymic CarcinomaKyoichi Kaira, Hisao Imai, Ou Yamaguchi, et al.
Current Oncology Reports|July 2, 2024
Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint InhibitorsKyoichi Kaira, Atsuto Mouri, Hisao Imai, et al.
Medicina (Kaunas, Lithuania)|November 27, 2021
Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance StatusKyoichi Kaira, Hisao Imai, Atsuto Mouri, et al.
Medicine|September 29, 2020
Osimertinib induced cardiomyopathy: A case reportShun Shinomiya, Kyoichi Kaira, Ou Yamaguchi, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|November 12, 2011
[A case of cutaneous vasculitis caused by erlotinib treatment and a review of literature]Yoko Takahashi, Noriyuki Ebi, Ou Yamaguchi, et al.
Translational Lung Cancer Research|January 9, 2026
Metabolic tumor volume on 18F-fluorodeoxyglucose uptake as prognostic marker for osimertinib in patients with non-small cell lung cancer harboring sensitive EGFR mutationKosuke Hashimoto, Kyoichi Kaira, Hisao Imai, et al.
Thoracic Cancer|March 13, 2019
Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancerAtsuto Mouri, Kyoichi Kaira, Ayako Shiono, et al.
Translational Lung Cancer Research|October 24, 2025
Prognostic biomarkers for extensive-stage small cell lung cancer receiving amrubicin following failure of chemoimmunotherapy: a retrospective cohort studyKyoichi Kaira, Hisao Imai, Kosuke Hashimoto, et al.
Respiratory Medicine Case Reports|March 11, 2026
Synchronous occurrence of interstitial lung disease and ICANS after tarlatamab initiation in recurrent small-cell lung cancerMasakazu Takahara, Atsuto Mouri, Ou Yamaguchi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Real-world occurrence of severe gastrointestinal bleeding in patients receiving amivantamab plus lazertinib: A two-case series among 25 consecutive casesKosuke Hashimoto, Masakazu Takahara, Reina Ishii, et al.
Pageof 10